View Financial HealthProvexis 배당 및 자사주 매입배당 기준 점검 0/6Provexis 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-2.0%자사주 매입 수익률총 주주 수익률-2.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025공고 • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomReported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.공고 • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomNew Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.2m market cap, or US$17.6m).New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.5m market cap, or US$17.8m).Reported Earnings • Oct 01Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022)Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.공고 • Sep 30Provexis plc, Annual General Meeting, Oct 26, 2023Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters.New Risk • Jul 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (€14.8m market cap, or US$16.2m).Reported Earnings • Dec 31First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022)First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Oct 14Provexis plc Announces Directorate ChangeProvexis, announced the resignation of Frédéric Boned, a Non-executive Director of the Company, with immediate effect. Frédéric Boned joined the Board of Provexis as a Non-executive Director in July 2018, at which point he was EMEA Vice President of DSM's Human Nutrition & Health business, a part of DSM Nutritional Products. Frédéric, who is currently Regional Vice President Health Nutrition & Care North America at DSM, has announced his resignation from DSM with effect from 15 October 2022.Reported Earnings • Oct 01Full year 2022 earnings releasedFull year 2022 results: Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021).공고 • Oct 01+ 1 more updateProvexis plc to Report Q1, 2023 Results on Sep 30, 2022Provexis plc announced that they will report Q1, 2023 results on Sep 30, 2022공고 • Jun 22Provexis plc Announces the Filing of New Patent ApplicationProvexis plc announced the filing of a new patent application relating to the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans. This follows the completion of a successful human study, the results of which (as stated in the patent application) strongly support the use of Fruitflow for modulating gut microbiota to confer a number of health benefits.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Nov 16Provexis plc Announces Exclusive Distribution Agreement for Chinese CBECProvexis announced it has entered into a distribution agreement with a company ('the Distributor') which will act as the distributor for Fruitflow+ Omega-3 in China, exclusively through the Chinese Cross-Border e-commerce ('CBEC') channel. CBEC regulations include a waiver of the existing Chinese pre-importation registration requirements on specified categories of products, permitting overseas exporters to sell consumer goods directly to Chinese consumers through certain registered e-commerce platforms. The agreement announced grants the Distributor exclusive rights to import, market and sell the Company's Fruitflow+ Omega-3 dietary supplement product in China through the CBEC channel, with immediate effect. The Distributor will purchase Fruitflow+ Omega-3 as required from the Company, and the Distributor will then market and sell Fruitflow+ Omega-3 in China through its existing network of e-commerce and other sales channels. The Company has recently completed a redesign of the existing Fruitflow+ Omega-3 packaging, to include a new single blister pack format, with this new packaging having been optimised for sales through CBEC by the Distributor in China.Reported Earnings • Oct 01Full year earnings released - €0.0002 loss per shareOver the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NZCA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NZCA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Provexis 배당 수익률 vs 시장NZCA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NZCA)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.8%업계 평균 (Personal Products)2.5%분석가 예측 (NZCA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NZCA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NZCA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NZCA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NZCA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/15 23:43종가2026/07/15 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Provexis plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025
공고 • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
Reported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
공고 • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
New Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.2m market cap, or US$17.6m).
New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.5m market cap, or US$17.8m).
Reported Earnings • Oct 01Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022)Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
공고 • Sep 30Provexis plc, Annual General Meeting, Oct 26, 2023Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters.
New Risk • Jul 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (€14.8m market cap, or US$16.2m).
Reported Earnings • Dec 31First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022)First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Oct 14Provexis plc Announces Directorate ChangeProvexis, announced the resignation of Frédéric Boned, a Non-executive Director of the Company, with immediate effect. Frédéric Boned joined the Board of Provexis as a Non-executive Director in July 2018, at which point he was EMEA Vice President of DSM's Human Nutrition & Health business, a part of DSM Nutritional Products. Frédéric, who is currently Regional Vice President Health Nutrition & Care North America at DSM, has announced his resignation from DSM with effect from 15 October 2022.
Reported Earnings • Oct 01Full year 2022 earnings releasedFull year 2022 results: Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021).
공고 • Oct 01+ 1 more updateProvexis plc to Report Q1, 2023 Results on Sep 30, 2022Provexis plc announced that they will report Q1, 2023 results on Sep 30, 2022
공고 • Jun 22Provexis plc Announces the Filing of New Patent ApplicationProvexis plc announced the filing of a new patent application relating to the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans. This follows the completion of a successful human study, the results of which (as stated in the patent application) strongly support the use of Fruitflow for modulating gut microbiota to confer a number of health benefits.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Nov 16Provexis plc Announces Exclusive Distribution Agreement for Chinese CBECProvexis announced it has entered into a distribution agreement with a company ('the Distributor') which will act as the distributor for Fruitflow+ Omega-3 in China, exclusively through the Chinese Cross-Border e-commerce ('CBEC') channel. CBEC regulations include a waiver of the existing Chinese pre-importation registration requirements on specified categories of products, permitting overseas exporters to sell consumer goods directly to Chinese consumers through certain registered e-commerce platforms. The agreement announced grants the Distributor exclusive rights to import, market and sell the Company's Fruitflow+ Omega-3 dietary supplement product in China through the CBEC channel, with immediate effect. The Distributor will purchase Fruitflow+ Omega-3 as required from the Company, and the Distributor will then market and sell Fruitflow+ Omega-3 in China through its existing network of e-commerce and other sales channels. The Company has recently completed a redesign of the existing Fruitflow+ Omega-3 packaging, to include a new single blister pack format, with this new packaging having been optimised for sales through CBEC by the Distributor in China.
Reported Earnings • Oct 01Full year earnings released - €0.0002 loss per shareOver the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year.